Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
TFFP

TFFP - TFF Pharmaceuticals Inc Stock Price, Fair Value and News

$0.060.00 (0.00%)
Market Closed

TFFP Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

TFFP Price Action

TFFP RSI Chart

TFFP Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

TFFP Valuation

TFFP Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

TFFP Fundamentals

TFFP Revenue

TFFP Earnings

TFFP Profitability

TFFP Investor Care

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2024885.7K1.2M1.2M0
2023479.8K785.1K932.3K733.9K
2022131.3K157.4K195.0K495.8K
202100088.2K
Get all data in R, Python etc through our Historical Stock Data APIs

About TFF Pharmaceuticals Inc

TFFP
TFF Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company's drug candidates are TFF Voriconazole Inhalation Powder, which is in Phase II clinical trials for the treatment of invasive pulmonary aspergillosis; and TFF Tacrolimus Inhalation Powder, which is in Phase II clinical trials used to prevent lung transplant rejection. It is also developing other dry powder products, such as Augmenta monoclonal antibodies for the treatment of COVID-19 therapeutics; TFF Niclosamide, which is completed Phase 1 clinical trials for the treatment of COVID-19 disease; and other vaccines. TFF Pharmaceuticals, Inc. has a license agreement with the University of Texas at Austin for the development of inhaled dry powder drugs; a joint development agreement with Augmenta Bioworks, Inc. to develop Augmenta monoclonal antibodies; a licensing and collaboration agreement with UNION therapeutics A/S; and a collaborative research and development agreement with the National Institute of Environmental Health Sciences to develop dry powder formulations of hyaluronan to prevent and treat respiratory diseases. The company was incorporated in 2018 and is headquartered in Fort Worth, Texas.
 CEO
 WEBSITEhttps://tffpharma.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES15